Literature DB >> 9844122

Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium.

V Panichi1, S De Pietro, B Andreini, A M Bianchi, M Migliori, D Taccola, L Giovannini, C Tetta, R Palla.   

Abstract

Calcitriol modulates in vivoand in vitro cytokine production: A role for intracellular calcium. Background. Several immunomodulatory properties of calcitriol are currently known, however, only little information is available regarding the in vivo and in vitro effects of calcitriol on cytokine production in chronic renal failure. Methods. To study the in vitro effect of calcitriol on lipopolysaccharide (LPS)-induced cytokine production, peripheral blood mononuclear cells (PBMC, 2.5 ml/ml) from 12 chronic dialytic (HD), 15 undialyzed chronic renal failure (CRF) patients and 10 normal subjects (N) were incubated at 37 degrees for 12 hours with 100 ng of LPS (E. coli and P. maltofilia). Increasing doses of calcitriol from 10-10 to 10-9 M were added and cell associated TNF-alpha and IL-1beta were determined by immunoreactive tests after three freeze-thaw cycles. The intradialytic TNF-alpha and IL-1beta production were evaluated in vivo in 12 HD patients before and after three months of intravenous calcitriol treatment (6 microgram/week). Intracellular calcium [Ca++]i was determined on PBMC with a cytofluorimetric assay using FLUO-3 AM as the indicator. Results. In vitro, TNF-alpha increased from 3.6 +/- 1.9 pg/cell to 1797 +/- 337 in N, from 4.5 +/- 1.7 to 1724 +/- 232 in CRF and from 3.4 +/- 2.3 to 1244 +/- 553 in HD after the LPS stimulus. The production of TNF-alpha was inhibited by calcitriol in a dose-dependent manner [LPS + Vit.D3 100 ng, 2.9 +/- 2.1 in N, 3.7 +/- 1.9 in CRF and 3.4 +/- 1.7 in HD; LPS + Vit.D3 50 ng, 263 +/- 296 (N), 6.73 +/- 11 (CRF), 38 +/- 28 (HD); LPS + Vit.D3 25 ng = 873 +/- 583 (N), 325 +/- 483 (CRF), 588 +/- 507 (HD); LPS + Vit.D3 12.5 ng, 954 +/- 483 (N), 912 +/- 510 (CRF), 875 +/- 527 (HD)]. Comparable data were observed on IL-1beta production. In vivo, the intradialytic TNF-alpha increase (from 8.5 +/- 2.3 to 19 +/- 5.6 pg/2.5 x 106 cell) during hemodialysis was markedly reduced after calcitriol therapy (from 6.6 +/- 3.1 to 11 +/- 4.7). [Ca++]i decreased from 105 +/- 25 to 72 +/- 18 nM (P < 0.05) and a positive correlation between cytokine levels and [Ca++]i was found (r = 0.79; P < 0.001). Conclusions. The in vitro increase of cell-associated cytokine after LPS challenge was inhibited by calcitriol in a dose-dependent manner. These data suggest a possible in vivo modulatory effect of calcitriol therapy on cytokine production in hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9844122     DOI: 10.1046/j.1523-1755.1998.00152.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  30 in total

Review 1.  Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.

Authors:  Chia Chi Sun; Valentina Vaja; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Hematol       Date:  2012-01-31       Impact factor: 10.047

2.  Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate.

Authors:  Ian H de Boer; Ronit Katz; Michel Chonchol; Joachim H Ix; Mark J Sarnak; Michael G Shlipak; David S Siscovick; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-11       Impact factor: 8.237

3.  Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort.

Authors:  Samar R El Khoudary; Saad Samargandy; Irfan Zeb; Temitope Foster; Ian H de Boer; Dong Li; Matthew J Budoff
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-09-10       Impact factor: 4.222

4.  Vitamin D and Atherosclerotic Cardiovascular Disease.

Authors:  Thomas Hiemstra; Kenneth Lim; Ravi Thadhani; JoAnn E Manson
Journal:  J Clin Endocrinol Metab       Date:  2019-04-04       Impact factor: 5.958

5.  Active vitamin D and acute respiratory infections in dialysis patients.

Authors:  Yoshihiro Tsujimoto; Hideki Tahara; Tetsuo Shoji; Masanori Emoto; Hidenori Koyama; Eiji Ishimura; Tsutomu Tabata; Yoshiki Nishizawa; Masaaki Inaba
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

Review 6.  Vitamin D and Calcimimetics in Cardiovascular Disease.

Authors:  Kenneth Lim; Takayuki Hamano; Ravi Thadhani
Journal:  Semin Nephrol       Date:  2018-05       Impact factor: 5.299

7.  Vitamin D deficiency and anemia: a cross-sectional study.

Authors:  John J Sim; Peter T Lac; In Lu A Liu; Samuel O Meguerditchian; Victoria A Kumar; Dean A Kujubu; Scott A Rasgon
Journal:  Ann Hematol       Date:  2009-10-20       Impact factor: 3.673

8.  Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events.

Authors:  Sachiyo Sugiura; Daijo Inaguma; Akimitsu Kitagawa; Minako Murata; Yutaka Kamimura; Sho Sendo; Kyoko Hamaguchi; Hiroshi Nagaya; Miho Tatematsu; Kei Kurata; Yukio Yuzawa; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2009-10-31       Impact factor: 2.801

9.  Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study.

Authors:  M Kyla Shea; Sarah L Booth; Joseph M Massaro; Paul F Jacques; Ralph B D'Agostino; Bess Dawson-Hughes; José M Ordovas; Christopher J O'Donnell; Sekar Kathiresan; John F Keaney; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am J Epidemiol       Date:  2007-11-15       Impact factor: 4.897

10.  The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial.

Authors:  William G Petchey; Ingrid J Hickman; Emma Duncan; Johannes B Prins; Carmel M Hawley; David W Johnson; Katherine Barraclough; Nicole M Isbel
Journal:  BMC Nephrol       Date:  2009-12-10       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.